Carbacyclin

Carbacyclin is a PGI2 analogue, acts as a prostacyclin (PGI2) receptor agonist and vasodilator, and potently inhibits platelet aggregation.

Product Specifications

CAS Number

[69552-46-1]

Product Name Alternative

Carbaprostacyclin; Carba-PGI2

UNSPSC

12352211

Hazard Statement

H302, H312, H332

Target

PPAR; Prostaglandin Receptor

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; GPCR/G Protein; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Carbacyclin.html

Concentration

2.85 mM * 100 μL in Methyl acetate

Purity

99.0

Smiles

O=C(O)CCC/C=C1C[C@@]2([H])C[C@@H](O)[C@H](/C=C/[C@@H](O)CCCCC)[C@@]2([H])C\1

Molecular Formula

C21H34O4

Molecular Weight

350.49

Precautions

H302, H312, H332

References & Citations

[1]Takasuka M, et al. FTIR spectral study of intramolecular hydrogen bonding in thromboxane A2 receptor agonist (U-46619), prostaglandin (PG) E2, PGD2, PGF2 alpha, prostacyclin receptor agonist (carbacyclin), and their related compounds in dilute CCl4 solution: structure-activity relationships. J Med Chem. 1994 Jan 7;37 (1) :47-56.|[2]Whittle BJ, et al. Carbacyclin--a potent stable prostacyclin analogue for the inhibition of platelet aggregation. Prostaglandins. 1980 Apr;19 (4) :605-27.|[3]Kuroda T, et al. Carbacyclin induces carnitine palmitoyltransferase-1 in cardiomyocytes via peroxisome proliferator-activated receptor (PPAR) delta independent of the IP receptor signaling pathway. J Mol Cell Cardiol. 2007 Jul;43 (1) :54-62.